Fructooligosaccharides (FOS) ： Irritable Bowel Syndrome (IBS)
D 研究 予備的な研究（実験室研究、症例報告）のみが存在します。Mixed results. Low doses may help (5 g) but higher doses can worsen bloating due to rapid fermentation.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dfructooligosaccharides\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
結論
Mixed results. Low doses may help (5 g) but higher doses can worsen bloating due to rapid fermentation.
Key Study Findings
Other
FODMAP Profile of Wholegrain Pasta.
Dose: None
vs: None
Outcome: FODMAP compound content in pasta (analytical)
効果: None
None
対象集団: Commercially available pasta products (analytical study)
Randomized Controlled Trial
n=9
12 weeks
Modification of the Low FODMAP Diet Is Feasible in the Treatment of Irritable Bowel Syndrome: …
Dose: None
vs: Baseline; crossover between 3 diets
Outcome: Birmingham IBS questionnaire symptom score
効果: 75% relief on low FOS+GOS; 62.5% on FODMAP
p<0.05
対象集団: IBS patients (Rome IV criteria)
Other
Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers.
Dose: None
vs: Standard wholegrain flour products
Outcome: FODMAP content reduction in cookies and crackers
効果: Up to 99.5% FODMAP reduction (wheat malt)
None
対象集団: Laboratory food science study (no human subjects)
Randomized Controlled Trial
12 weeks
Double-blind
Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides …
Dose: None
vs: Placebo
Outcome: Quality of life
効果: None
p = 0.023
対象集団: IBS patients
In Vitro
Microbial inulinase promotes fructan hydrolysis under simulated gastric conditions.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: None
Controlled Clinical Trial
n=54
3.0 weeks
[Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with …
Dose: 350 mg
vs: None
Outcome: IBS symptom improvement
効果: None
None
対象集団: Irritable bowel syndrome with diarrhea and antibiotic-associated diarr
Key Statistics
2
研究数
150
参加者数
↔
Mixed
D
グレード
Referenced Papers
Foods (Basel, Switzerland)
2025
3 件の引用
Foods (Basel, Switzerland)
2025
1 件の引用
Gastroenterology research and …
2025
Journal of clinical …
2024
4 件の引用
Frontiers in nutrition
2023
8 件の引用
Voprosy pitaniia
2023
Carbohydrate polymers
2022
77 件の引用
FASEB journal : …
2022
16 件の引用
Journal of clinical …
2022
12 件の引用
Nutrients
2022
8 件の引用
Expert review of …
2022
8 件の引用
Food chemistry: X
2021
64 件の引用
Foods (Basel, Switzerland)
2021
10 件の引用
Nutrients
2020
78 件の引用
Journal of agricultural …
2018
13 件の引用
Neurogastroenterology and motility
2017
131 件の引用
Nutrition journal
2017
10 件の引用
Voprosy pitaniia
2013
The American journal …
2000
136 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 2-10 g/day
- prebioticeffect:
- 5-8 g/day for bifidogenic effect
- constipationsupport:
- 5-10 g/day
上限量： Well-tolerated up to 20 g/day; start low to avoid excess gas
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Neutral | -- |
| None | 12 weeks | Positive | 9 |
| None | -- | Positive | -- |
| None | 12 weeks | Positive | -- |
| None | -- | Mixed | -- |
| 350 mg | 3.0 weeks | Positive | 54 |
| None | -- | Mixed | -- |
| None | -- | Negative | -- |
推奨摂取タイミング： With meals; divide doses throughout the day
Safety & Side Effects
報告されている副作用
- ⚠ Gas, bloating, and flatulence (dose-dependent; more common above 10 g/day)
- ⚠ Abdominal cramping at higher doses
- ⚠ May worsen IBS symptoms in FODMAP-sensitive individuals
- ⚠ Loose stools at excessive doses
既知の相互作用
- ● Other FODMAPs (cumulative fermentation effect in sensitive individuals)
- ● Blood sugar-lowering medications (FOS may modestly affect glycemic response)
- ● Calcium supplements (FOS may enhance calcium absorption)
耐容上限摂取量： Well-tolerated up to 20 g/day; start low to avoid excess gas
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Fructooligosaccharides (FOS) help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Fructooligosaccharides (FOS) may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).
How much Fructooligosaccharides (FOS) should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 2-10 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Fructooligosaccharides (FOS)?
Reported side effects may include Gas, bloating, and flatulence (dose-dependent; more common above 10 g/day), Abdominal cramping at higher doses, May worsen IBS symptoms in FODMAP-sensitive individuals, Loose stools at excessive doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Fructooligosaccharides (FOS) and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is mixed.
Related Evidence
に関する他の成分： Irritable Bowel Syndrome (IBS)
Fructooligosaccharides (FOS) 他の症状・状態について
References
- [1] Aleksandra M Torbica et al.. Foods. 2025. FODMAP Profile of Wholegrain Pasta. doi:10.3390/foods14040667 PubMed
- [2] Aleksandra M Torbica et al.. Foods. 2025. Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers. doi:10.3390/foods14040582 PubMed
- [3] Line Graser Jensen et al.. Gastroenterol Res Pract. 2025. Modification of the Low FODMAP Diet Is Feasible in the Treatment of Irritable Bowel Syndrome: A Randomised Crossover Study. doi:10.1155/grp/4152978 PubMed
- [4] Anita Gąsiorowska et al.. J Clin Med. 2024. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel … doi:10.3390/jcm14010006 PubMed
- [5] Justin L Guice et al.. Front Nutr. 2023. Microbial inulinase promotes fructan hydrolysis under simulated gastric conditions. doi:10.3389/fnut.2023.1129329 PubMed
- [6] V N Drozdov et al.. Vopr Pitan. 2023. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea … doi:10.33029/0042-8833-2023-92-4-92-103 PubMed
- [7] Ashinshana U Illippangama et al.. Carbohydr Polym. 2022. Inulin as a functional ingredient and their applications in meat products. doi:10.1016/j.carbpol.2021.118706 PubMed
- [8] J B J Kamphuis et al.. FASEB J. 2022. Increased fermentable carbohydrate intake alters colonic mucus barrier function through glycation processes and increased mast cell counts. doi:10.1096/fj.202100494RRR PubMed
- [9] Anita Gąsiorowska et al.. J Clin Med. 2022. Effects of Microencapsulated Sodium Butyrate, Probiotics and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome: A Study Protocol of … doi:10.3390/jcm11216587 PubMed
- [10] Susie Jung et al.. Nutrients. 2022. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Multi-Strain Synbiotic in Patients with Functional Diarrhea and High Fecal … doi:10.3390/nu14235017 PubMed
- [11] Diego Currò. Expert Rev Gastroenterol Hepatol. 2022. Current evidence on the therapeutic use of fiber in irritable bowel syndrome. doi:10.1080/17474124.2021.1924057 PubMed
- [12] Marcel Skejovic Joehnke et al.. Food Chem X. 2021. Nutritional and anti-nutritional properties of lentil (Lens culinaris) protein isolates prepared by pilot-scale processing. doi:10.1016/j.fochx.2020.100112 PubMed
- [13] Johannes Pitsch et al.. Foods. 2021. FODMAP Fingerprinting of Bakery Products and Sourdoughs: Quantitative Assessment and Content Reduction through Fermentation. doi:10.3390/foods10040894 PubMed
- [14] Barbara Skrzydło-Radomańska et al.. Nutrients. 2020. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant … doi:10.3390/nu12071999 PubMed
- [15] Tobias Pöhnl et al.. J Agric Food Chem. 2018. Impact of Cultivation Method and Cultivar Selection on Soluble Carbohydrates and Pungent Principles in Onions ( Allium cepa L.). doi:10.1021/acs.jafc.8b05018 PubMed
- [16] F Azpiroz et al.. Neurogastroenterol Motil. 2017. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double … doi:10.1111/nmo.12911 PubMed
- [17] Jennifer Erickson et al.. Nutr J. 2017. Gastrointestinal tolerance of low FODMAP oral nutrition supplements in healthy human subjects: a randomized controlled trial. doi:10.1186/s12937-017-0256-3 PubMed
- [18] V I Pilipenko et al.. Vopr Pitan. 2013. [Contemporary dietotherapy of the irritable bowel syndrome]. PubMed
- [19] M Olesen et al.. Am J Clin Nutr. 2000. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. doi:10.1093/ajcn/72.6.1570 PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。